دورية أكاديمية
Patch Testing With Benzophenone-3 and -4: The North American Contact Dermatitis Group Experience, 2013-2020.
| العنوان: | Patch Testing With Benzophenone-3 and -4: The North American Contact Dermatitis Group Experience, 2013-2020. |
|---|---|
| المؤلفون: | Warshaw EM; From the Department of Dermatology, Park Nicollet/Health Partners Health Services, Minneapolis, Minnesota, USA.; Department of Dermatology, University of Minnesota, Minneapolis, Minnesota, USA.; Department of Dermatology, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota, USA., Xiong M; From the Department of Dermatology, Park Nicollet/Health Partners Health Services, Minneapolis, Minnesota, USA.; Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA., Belsito DV; Department of Dermatology, Columbia University Irving Medical School, New York, New York, USA., Adler BL; Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA., Atwater AR; Department of Dermatology, Duke University Medical Center, Durham, North Carolina, USA., DeKoven JG; Division of Dermatology, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada., Taylor JS; Department of Dermatology, Cleveland Clinic, Cleveland, Ohio, USA., Reeder MJ; Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA., Houle MC; Division of Dermatology, Centre Hospitalier Universitaire de Québec, Laval University, Québec, Canada., Silverberg JI; Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA., Pratt MD; Division of Dermatology, University of Ottawa, Ontario, Canada., Dunnick CA; Department of Dermatology, University of Colorado, Aurora, Colorado, USA., Botto N; Department of Dermatology, University of California San Francisco, San Francisco, California, USA., DeLeo VA; From the Department of Dermatology, Park Nicollet/Health Partners Health Services, Minneapolis, Minnesota, USA., Mowad CM; Division of Dermatology, Geisinger Medical Center, Danville, Pennsylvania, USA., Maibach HI; Department of Dermatology, University of California San Francisco, San Francisco, California, USA., Yu J; Department of Dermatology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts, USA., Fowler JF Jr; Division of Dermatology, University of Louisville, Louisville, Kentucky, USA. |
| المصدر: | Dermatitis : contact, atopic, occupational, drug [Dermatitis] 2023 Mar-Apr; Vol. 34 (2), pp. 105-112. Date of Electronic Publication: 2023 Jan 19. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Mary Ann Liebert Country of Publication: United States NLM ID: 101207335 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2162-5220 (Electronic) Linking ISSN: 17103568 NLM ISO Abbreviation: Dermatitis Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : New Rochelle, NY : Mary Ann Liebert Original Publication: Hamilton, Ont. : BC Decker, c2004- |
| مواضيع طبية MeSH: | Sunscreening Agents*/adverse effects , Dermatitis, Allergic Contact*/diagnosis , Dermatitis, Allergic Contact*/epidemiology , Dermatitis, Allergic Contact*/etiology, Humans ; Patch Tests/adverse effects ; Retrospective Studies ; Allergens ; Benzophenones/adverse effects ; North America/epidemiology |
| مستخلص: | Background: Benzophenone (BZP)-3 and BZP-4 are ultraviolet (UV) absorbers used in sunscreens and personal care products (PCPs) and may cause allergic contact dermatitis. Objective: To characterize positive patch test reactions to BZP-3 (10% in petrolatum [pet]) and BZP-4 (2% pet) in a screening allergen series. Methods: Retrospective analysis of patients tested to BZP-3 and BZP-4 was conducted by the North American Contact Dermatitis Group from 2013 to 2020. Results: Of 19,618 patients patch tested to BZP-3 and BZP-4, 103 (0.5%) and 323 (1.6%) had positive reactions, respectively: 413 (2.1%) reacted to at least 1 BZP (BZP-positive patient). As compared with BZP-negative patients, BZP-positive patients were significantly more likely to have a history of hay fever (39.3% vs 33.4%, P = 0.0134), history of atopic dermatitis (39.8% vs 30.7%, P = 0.0001), and facial involvement (37.4% vs 32.2%, P = 0.0272). Most reactions were currently clinically relevant (BZP-3: 90.4%; BZP-4: 65.8%). Common identified sources included PCPs and sunscreens. Coreactivity between BZP-3 and BZP-4 was low: 13.5% (14/104) of BZP-3-positive patients were allergic to BZP-4 and 4.3% (14/322) of BZP-4-positive patients were allergic to BZP-3. Conclusions: Eight-year prevalence of BZP positivity was 2.1%. Reactions were frequently clinically relevant and linked to PCPs and sunscreens. |
| المشرفين على المادة: | 95OOS7VE0Y (oxybenzone) 0 (Sunscreening Agents) 0 (Allergens) 1W6L629B4K (sulisobenzone) 0 (Benzophenones) |
| تواريخ الأحداث: | Date Created: 20230314 Date Completed: 20230322 Latest Revision: 20230322 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1089/derm.2022.29013.ewa |
| PMID: | 36917534 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2162-5220 |
|---|---|
| DOI: | 10.1089/derm.2022.29013.ewa |